1887
  1. Home
  2. Eurosurveillance
  3. Volume 26, Issue 26, 01/Jul/2021
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

SARS-CoV-2 Delta (B.1.617.2) variant of concern (VOC) and other VOCs are spreading in Europe. Micro-neutralisation assays with sera obtained after Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in 36 healthcare workers (31 female) demonstrated significant fold change reduction in neutralising titres compared with the original virus: Gamma (P.1) 2.3, Beta (B.1.351) 10.4, Delta 2.1 and 2.6. The reduction of the Alpha (B.1.1.7) variant was not significant. Despite being lower, remaining neutralisation capacity conferred by Comirnaty against Delta and other VOCs is probably protective.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2021.26.26.2100557
2021-07-01
2024-04-25
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2021.26.26.2100557
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/26/26/eurosurv-26-26-2.html?itemId=/content/10.2807/1560-7917.ES.2021.26.26.2100557&mimeType=html&fmt=ahah

References

  1. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. , C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.  https://doi.org/10.1056/NEJMoa2034577  PMID: 33301246 
  2. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-29.  https://doi.org/10.1016/S0140-6736(21)00947-8  PMID: 33964222 
  3. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384(15):1412-23.  https://doi.org/10.1056/NEJMoa2101765  PMID: 33626250 
  4. Leung K, Shum MH, Leung GM, Lam TT, Wu JT. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill. 2021;26(1).  https://doi.org/10.2807/1560-7917.ES.2020.26.1.2002106  PMID: 33413740 
  5. Makoni M. South Africa responds to new SARS-CoV-2 variant. Lancet. 2021;397(10271):267.  https://doi.org/10.1016/S0140-6736(21)00144-6  PMID: 33485437 
  6. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DDS, Mishra S, et al. Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. Science. 2021;372(6544):815-21.  https://doi.org/10.1126/science.abh2644  PMID: 33853970 
  7. Singh J, Rahman SA, Ehtesham NZ, Hira S, Hasnain SE. SARS-CoV-2 variants of concern are emerging in India. Nat Med. 2021.  https://doi.org/10.1038/s41591-021-01397-4  PMID: 34045737 
  8. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754-60.  https://doi.org/10.1093/bioinformatics/btp324  PMID: 19451168 
  9. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. Nextstrain: real-time tracking of pathogen evolution. Bioinformatics. 2018;34(23):4121-3.  https://doi.org/10.1093/bioinformatics/bty407  PMID: 29790939 
  10. Lustig Y, Nemet I, Kliker L, Zuckerman N, Yishai R, Alroy-Preis S, et al. Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2. N Engl J Med. 2021;384(25):2453-4.  https://doi.org/10.1056/NEJMc2104036  PMID: 33826815 
  11. Wang P, Casner RG, Nair MS, Wang M, Yu J, Cerutti G, et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021 May 12;29(5):747-51 e4.
  12. Liu Y, Liu J, Xia H, Zhang X, Zou J, Fontes-Garfias CR, et al. BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. N Engl J Med. 2021;NEJMc2106083.  https://doi.org/10.1056/NEJMc2106083  PMID: 33979486 
  13. Cherian S, Potdar V, Jadhav S, Yadav P, Gupta N, Das M, et al. Panda S Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. bioRxiv. 2021.  https://doi.org/10.1101/2021.04.22.440932 
  14. Callaway E. Delta coronavirus variant: scientists brace for impact. Nature. 2021 Jun 22.  https://doi.org/http://dx.doi.org/10.1038/d41586-021-01696-3 . PMID: 34158664
  15. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, et al. Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell. 2021. Available from: https://www.cell.com/action/showPdf?pii=S0092-8674%2821%2900755-8
  16. Shen X, Tang H, Pajon R, Smith G, Glenn GM, Shi W, et al. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. N Engl J Med. 2021;384(24):2352-4.  https://doi.org/10.1056/NEJMc2103740  PMID: 33826819 
  17. Virtanen J, Uusitalo R, Korhonen EM, Aaltonen K, Smura T, Kuivanen S, et al. Kinetics of Neutralizing Antibodies of COVID-19 Patients Tested Using Clinical D614G, B.1.1.7, and B 1.351 Isolates in Microneutralization Assays. Viruses. 2021;13(6):996.  https://doi.org/10.3390/v13060996  PMID: 34073577 
  18. Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. N Engl J Med. 2021;NEJMc2104974.  https://doi.org/10.1056/NEJMc2104974  PMID: 33951357 
Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Yaniv+Lustig&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Lustig Yaniv</a>, <a href="/search?value1=Neta+Zuckerman&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zuckerman Neta</a>, <a href="/search?value1=Ital+Nemet&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Nemet Ital</a>, <a href="/search?value1=Nofar+Atari&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Atari Nofar</a>, <a href="/search?value1=Limor+Kliker&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Kliker Limor</a>, <a href="/search?value1=Gili+Regev-Yochay&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Regev-Yochay Gili</a>, <a href="/search?value1=Einav+Sapir&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sapir Einav</a>, <a href="/search?value1=Orna+Mor&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mor Orna</a>, <a href="/search?value1=Sharon+Alroy-Preis&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Alroy-Preis Sharon</a>, <a href="/search?value1=Ella+Mendelson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mendelson Ella</a>, <a href="/search?value1=Michal+Mandelboim&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mandelboim Michal</a></span>. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. <a href="/content/ecdc">Euro Surveill.</a> 2021;26(26):pii=2100557. <a href="https://doi.org/10.2807/1560-7917.ES.2021.26.26.2100557" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2021.26.26.2100557</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 03 Jun 2021;&nbsp;&nbsp; <span class="generated">Accepted</span>: 01 Jul 2021 </span> </p>
/content/10.2807/1560-7917.ES.2021.26.26.2100557
/content/10.2807/1560-7917.ES.2021.26.26.2100557
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error